[size=55:1a0lq8vp]Focus 19 November 2010
Amendments to Ministry of Health’s regulations to stop certain medicines
Amendments to Ministry of Health’s regulations will stop certain medicines’ production, said Iliya Pashov, managing director of Actavis-Bulgaria.
In his words, the changes will be a huge blow against the Bulgarian pharmaceutical industry.
“Bulgarian patients will be the one to suffer from it most. The announced changes concern the fact that when forming the price of the product that is missing in the eight reference countries, it will be referred to the price of the cheapest INN, produced in China or India. These products are very cheap and there is a logical explanation for it – cheap labour force, huge state subsidies for the pharmaceutical production, far-sighted state policy supporting the local pharmaceutical industry,” Pashov remarked.
“If the new paragraphs to article 7 are passed, we will be forced to stop the production of some of our well-recognised generic medicines because we will have to sell them at a price that is lower than their cost. If certain medicines are no longer produced it will be mainly to the detriment of Bulgarian patients, who place trust in these products and can afford them,” Pashov added.
He commented that amendments will also be an obstacle for Actavis to launch the first generic medicines at the Bulgarian market. This will hamper the provision of modern, efficient generic medicines of good quality at affordable prices right after the patents of the original medicines expire.